Medicus Pharma (NASDAQ:MDCX) announced plans to present new early-stage clinical data on its investigational drug candidate, Teverelix, at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas later this month.
The company said the presentation will include results from two Phase 1 studies evaluating Teverelix, a long-acting gonadotropin-releasing hormone (GnRH) antagonist being developed for hormone-related conditions. Potential applications include women’s health disorders such as endometriosis and uterine fibroids.
According to the company, the findings are based on trials conducted in Germany involving 48 healthy premenopausal women who received a single subcutaneous dose of the drug. The data focused on pharmacokinetics, pharmacodynamics, safety, and effects on bone turnover.
Medicus reported that Teverelix demonstrated dose-dependent suppression of estradiol levels, with some participants reaching ranges considered clinically relevant for therapeutic effect. The hormone suppression was described as consistent and reversible.
The company also highlighted a pharmacokinetic profile suggesting long-acting activity, including rapid initial absorption followed by sustained exposure over several weeks. The reported terminal half-life ranged from approximately two to three weeks, which may support less frequent dosing schedules.
In addition, bone turnover markers remained within normal ranges over the study period, with limited changes observed after 29 days. No unexpected safety concerns were reported in either study.
The data will be presented in a poster session on April 24 by the company’s chief medical officer Faisal Mehmud.
Medicus stated that the results provide a basis for further clinical development and may support future studies in patient populations across multiple indications.